The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Prominent among these are Cosentyx, Pluvicto, Kisqali, and Scemblix. These products form the backbone of the company's near-term revenue strategy and are crucial for meeting its growth targets.

Prominent among these are Cosentyx, Pluvicto, Kisqali, and Scemblix. These products form the backbone of the company's near-term revenue strategy and are crucial for meeting its growth targets.

Some of Novartis AG (NYSE:NVS)’s key drugs are its prostate cancer drug Pluvicto, heart disease drug Leqvio, leukemia treatment Scemblix, and breast cancer treatment Kisqali. Among these ...

Asciminib (Scemblix) has reinforced its position in the chronic myeloid leukemia (CML) treatment landscape, as updated 96-week data demonstrated its superiority over standard-of-care tyrosine kinase ...

Novartis announced positive, longer-term results from the pivotal phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 961. The study ...

Novartis's current product portfolio and pipeline are central to its growth strategy. Key products such as Cosentyx, Pluvicto, Kisqali, and Scemblix are expected to drive the company's mid-term ...

NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib). Scemblix demonstrated ...

NVS Presents Long-Term Data on Scemblix Novartis also announced positive, longer-term results from the phase III ASC4FIRST study on leukemia drug Scemblix (asciminib). Scemblix demonstrated sustained ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...

(IN BRIEF) The University of Glasgow is pioneering a project to use cosmic rays for non-invasive structural assessments of the UK’s ageing transport infrastructure. Led by Dr. David Mahon and ...